6. References
1. Vahratian, A., et al., Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021-2022. NCHS Data Brief, 2023(488): p. 1-8.2. Renz-Polster, H. and C. Scheibenbogen,[Post-COVID syndrome with fatigue and exercise intolerance: myalgic encephalomyelitis/chronic fatigue syndrome]. Inn Med (Heidelb), 2022. 63 (8): p. 830-839.3. Nacul, L., et al.,European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe. Medicina, 2021.57 (5): p. 510.4. Lim, E.J., et al., Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Transl Med, 2020. 18 (1): p. 100.5. Lutz, L., et al., Evaluation of Immune Dysregulation in an Austrian Patient Cohort Suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Biomolecules, 2021. 11 (9): p. 1359.6. Rasa, S., et al., Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Journal of Translational Medicine, 2018. 16 (1): p. 268.7. Untersmayr, E., et al., Immune Mechanisms Underpinning Long COVID: Collegium Internationale Allergologicum Update 2024. Int Arch Allergy Immunol, 2024. 185 (5): p. 489-502.8. Altmann, D.M., et al., The immunology of long COVID. Nature Reviews Immunology, 2023.9. Nagy-Szakal, D., et al., Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome. Microbiome, 2017. 5 (1): p. 44.10. Kratzer, B., et al.,Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19. Allergy, 2024.11. Tsounis, E.P., et al., Intestinal barrier dysfunction as a key driver of severe COVID-19. World J Virol, 2023. 12 (2): p. 68-90.12. Schwarze, J., et al., Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med, 2004. 169 (7): p. 801-5.13. Kim, T.S., et al.,Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. Journal of Experimental Medicine, 2010. 207 (6): p. 1161-1172.14. Choudhury, A., et al., Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis. Therap Adv Gastroenterol, 2022. 15 : p. 17562848221118403.15. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue, S., P. Board on the Health of Select, and M. Institute of, The National Academies Collection: Reports funded by National Institutes of Health , in Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness . 2015, National Academies Press (US) Copyright 2015 by the National Academy of Sciences. All rights reserved.: Washington (DC).16. Corman, V.M., et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance, 2020. 25 (3): p. 2000045.17. Vietzen, H., et al., Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19. Genet Med, 2021. 23 (5): p. 963-967.18. Cervia, C., et al., Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nature Communications, 2022. 13 (1): p. 446.19. Gupta, A. and G.S. Gupta, Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs. Molecular and Cellular Biochemistry, 2021. 476 (8): p. 2917-2942.20. Ali, Y.M., et al.,Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins. Frontiers in Immunology, 2021. 12 .21. Kedor, C., et al., A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nature Communications, 2022. 13 (1): p. 5104.22. Jack, D.L., et al.,Mannose-binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitidis serogroup B. J Infect Dis, 2001. 184 (9): p. 1152-62.23. Chohan, K., et al.,A review of respiratory manifestations and their management in Ehlers-Danlos syndromes and hypermobility spectrum disorders. Chron Respir Dis, 2021. 18 : p. 14799731211025313.24. Thwaites, P.A., P.R. Gibson, and R.E. Burgell, Hypermobile Ehlers-Danlos syndrome and disorders of the gastrointestinal tract: What the gastroenterologist needs to know. J Gastroenterol Hepatol, 2022. 37 (9): p. 1693-1709.25. Lakhani, C.M., et al., Repurposing large health insurance claims data to estimate genetic and environmental contributions in 560 phenotypes. Nat Genet, 2019. 51 (2): p. 327-334.26. Kendler, K.S., et al., A distinctive profile of family genetic risk scores in a Swedish national sample of cases of fibromyalgia, irritable bowel syndrome, and chronic fatigue syndrome compared to rheumatoid arthritis and major depression. Psychol Med, 2023. 53 (9): p. 3879-3886.27. Albright, F., et al.,Evidence for a heritable predisposition to Chronic Fatigue Syndrome. BMC Neurol, 2011. 11 : p. 62.28. Cevik, M., et al.,SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe, 2021. 2 (1): p. e13-e22.29. Rohrhofer, J., et al., Association between Epstein-Barr-Virus reactivation and development of Long-COVID fatigue. Allergy, 2023.78 (1): p. 297-299.30. Zollner, A., et al., Postacute COVID-19 is Characterized by Gut Viral Antigen Persistence in Inflammatory Bowel Diseases. Gastroenterology, 2022. 163 (2): p. 495-506.e8.31. Gaebler, C., et al., Evolution of antibody immunity to SARS-CoV-2. Nature, 2021. 591 (7851): p. 639-644.32. Jason, L.A. and J.A. Dorri, Predictors of impaired functioning among long COVID patients. Work, 2023. 74 (4): p. 1215-1224.33. Sudre, C.H., et al., Attributes and predictors of long COVID. Nat Med, 2021. 27 (4): p. 626-631.34. Gang, J., et al., Microbiota and COVID-19: Long-term and complex influencing factors. Front Microbiol, 2022. 13 : p. 963488.35. Kitchens, R.L. and P.A. Thompson, Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res, 2005. 11 (4): p. 225-9.36. Rohrhofer, J., et al., Immunological Patient Stratification in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Journal of Clinical Medicine, 2024. 13 (1): p. 275.37. Laugerette, F., et al., Postprandial Endotoxin Transporters LBP and sCD14 Differ in Obese vs. Overweight and Normal Weight Men during Fat-Rich Meal Digestion. Nutrients, 2020. 12 (6).38. Lau, E., et al., The role of I-FABP as a biomarker of intestinal barrier dysfunction driven by gut microbiota changes in obesity. Nutr Metab (Lond), 2016. 13 : p. 31.39. Szymanska, E., et al., Fecal Zonulin as a Noninvasive Biomarker of Intestinal Permeability in Pediatric Patients with Inflammatory Bowel Diseases-Correlation with Disease Activity and Fecal Calprotectin. J Clin Med, 2021.10 (17).40. Chelakkot, C., J. Ghim, and S.H. Ryu,Mechanisms regulating intestinal barrier integrity and its pathological implications. Experimental & Molecular Medicine, 2018.50 (8): p. 1-9.41. Hodzic, Z., et al., IL-33 and the intestine: The good, the bad, and the inflammatory. Cytokine, 2017.100 : p. 1-10.42. Wu, W.H., et al., Interleukin-1β secretion induced by mucosa-associated gut commensal bacteria promotes intestinal barrier repair. Gut Microbes, 2022. 14 (1): p. 2014772.